China's Vaccine Sector Shows Signs Of Recovery Following Scandals, Popular Boycott
This article was originally published in PharmAsia News
Executive Summary
BEIJING - In a sign that China's vaccine sector is beginning to recover from a series of scandals set in motion by allegations surrounding faulty products, the country's leading vaccine developer, Sinovac Biotech, has received a substantial new order for a hepatitis A defense that the Beijing government will administer to children across the capital
You may also be interested in...
CEO Of China's Leading Vaccine Producer Reveals Latest Vaccine Scandal Has Triggered A Sector-wide Boycott, Throwing Firm Into The Red
BEIJING - The chief executive officer of Sinovac Biotech, China's leading vaccine developer, told investors this week that the country's latest vaccine scandal had poisoned public perceptions so deeply that many citizens are boycotting the entire sector
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).